None listed
Conditions
Brief summary
This study will compare the short term bioavailability of 3 delivery systems containing Omega-3 oils (gel capsules versus two different MicroMAX powders - one formulated with milk protein-sugar and other with milk protein-sugar-resistant starch) together with a flavoured milk in individuals. Bioavailablilty will be assessed by measurement of EPA and DHA in blood/plasma. To investigate the bioavailability of EPS and DHA delivered in 3 formats after a 4 week intervention.
Interventions
This study will compare the bioavailability of 3 delivery systems containing omega-3 oils (gel capsules versus two different MicroMAX powders – one formulated with milk protein-sugar and other milk protein-sugar-resistant starch) together with a flavoured milk in individuals. Bioavailability will be assessed by measurement of EPA & DHA in blood/plasma.
This is a non-blinded, parallel design study in which participants will be randomised to receive one of the three treatments to be consumed over
This study will compare the bioavailability of 3 delivery systems containing omega-3 oils (gel capsules versus two different MicroMAX powders – one formulated with milk protein-sugar and other milk protein-sugar-resistant starch) together with a flavoured milk in individuals. Bioavailability will be assessed by measurement of EPA & DHA in blood/plasma. This is a non-blinded, parallel design study in which participants will be randomised to receive one of the three treatments to be consumed over a 4 week period immediately following a 4 week washout period. Participants will be asked to abstain from consuming high omega-3 foods throughout the 8 weeks (includes 4 week washout and 4 week intervention). The bioavailability of a daily dose of omega-3 oils delivered via the three above mentioned formats over 4 weeks is to be investigated. The two different MicroMAX powders (one formulated with milk protein-sugar and other milk protein-sugar-resistant starch) will each be provided in a daily dose of 8g containing 500mg/g omega-3 oil. The gel capsules will be given as a daily dose of 4 capsules (each capsule will contain 1000mg of omega-3 oil).
Sponsors
CSIRO Preventative Health Flagship
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Prevention
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Healthy volunteers
Yes
Inclusion criteria
(1) Male and Females aged between 18-70 years (2) Normal dietary habits (no medically prescribed diet, no slimming diet, and no vegan or macrobiotic diet). (3) Body Mass Index >18 kg/m^2 < 35kg/m^2 (calculation: Body Mass Index = weight in kg / height^2 in m^2). (4) Apparently healthy: no reported current or previous metabolic diseases, gastrointestinal disorders, renal or cardiovascular disease. (5) Person having given their specific consent in writing.
Exclusion criteria
(1) Regular use of supplements containing omega-3 essential fatty acids must have ceased 2 months prior to the start of the study. (2) Current relevant medical treatment (subject to judgement of the investigator). (3) High alcohol consumption (>21 standard drinks/week) (4) Reported participation in another biomedical trial 3 months before the start of the study or during the study. (5) Food allergies or intolerances (dairy, lactose, peanuts, shellfish, etc…). (6) Recent history (within 12 months) of substance abuse including alcohol abuse.
Outcome results
None listed